Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7267MR)

This product GTTS-WQ7267MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7267MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14000MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ3970MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ3049MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ11253MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ3433MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ5483MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ14060MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ4952MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW